Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Contract Signed with global IT leader ICT

14 Jul 2014 07:00

RNS Number : 1677M
Advanced Oncotherapy PLC
14 July 2014
 



 

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

 

Contract Signed with global IT leader ICT

 

Advanced Oncotherapy (AIM: AVO), the developer of the next generation of particle therapy with protons for cancer treatment, announces that they have contracted global technology leader ICT Automatisering ("ICT") to develop the software systems to manage patient workflow by the proprietary LIGHT accelerator.

 

The work flow for delivering cost effective proton beam therapy requires an integrated approach of all processes - from the first patient consultation to final day of treatment - to deliver the optimal treatment in each session.

 

With the acquisition of ADAM, a spin-off of CERN, Advanced Oncotherapy has developed the LIGHT accelerator to produce a high energy proton beam system in a most economical, efficient and cost-effective manner. The aim is to integrate the LIGHT accelerator within a fully-operational treatment facility including detailed data and process management to achieve the highest level of operational efficiency. This is achieved through tight integration of software and hardware solutions to ensure optimal interoperability.

 

AVO chose ICT after an extensive review because of their expertise in medical software standards, their domain knowledge in radiation therapy and their broad expertise in parallel industries.

 

AVO's Product Development team lead, Dr Hanne Kooy, Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School, commented: "ICT's extensive experience with work flow architecture ensures full utilisation of the unique LIGHT characteristics to maximise patient treatment outcomes."

 

Based in the Netherlands, ICT Automatisering provides high-quality IT solutions in information and communication technology, with a particular focus on Automotive, Machine & Systems, Industrial Automation, Logistics, Energy and Healthcare. ICT has an annual turnover of nearly €80m works across Europe in the Netherlands, Germany and Poland and employs approximately 750 highly qualified personnel.

 

Jan-Willem Doosje, Business Development Manager ICT Automatisering, commented: "We are proud to advise AVO on the complex infrastructure which is needed for the integration of their LIGHT accelerator in the radiation oncology department. Our experiences gained in applying the standards in Radiation Oncology such as set by DICOM and IHE-RO (Integrating the Healthcare Enterprise - Radiation Oncology) will be of added value for the design of the infrastructure needed for the Advanced Oncotherapy proton delivery solution."

 

Sanjeev Pandya, CEO of Advanced Oncotherapy, commented: "After a review of the specialist companies working in this area, we have chosen ICT because of their commercial expertise and their close working relationship with the authorities who review and regulate the use of radiation therapies. This is another significant step towards achieving our goal of delivering and installing our first LIGHT system at the beginning of 2016."

 

 

 

 

 

For further information contact:

 

Advanced Oncotherapy Plc

Sanjeev Pandya (CEO)

www.avoplc.com

Tel: +44 20 3617 8739

 

Westhouse Securities (Nomad & Joint Broker)

Tel: +44 (0)20 7601 6100

Antonio Bossi / David Coaten

Peterhouse Corporate Finance (Joint Broker)

Tel: +44 20 7469 0930

Lucy Williams

Walbrook PR (Financial PR & IR)

avo@walbrookpr.com

Anna Dunphy / Mike Wort

 

Tel: +44 20 7933 8780

 

About Advanced Oncotherapy Plc

 

AVO's team based at CERN near Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

AVO is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects.

 

AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care. 

 

For more information, please visit http://www.avoplc.com

 

About ICT Automatisering

ICT Automatisering's goal is to simplify and improve our clients' business, production and communication processes and to make them more flexible. We do this by using our high-grade technological expertise. We deploy this expertise in the form of inventive and effective product and market combinations. ICT is organised in line with the markets we serve. We have six verticals: Automotive, Industrial Automation, Logistics, Machine & Systems, Healthcare and Energy. Within each vertical professionals offer specific know-how and expertise of their market's products and processes. For more detailed information on ICT, visit our website at www.ict.eu.

 

 

 

About ICT's Healthcare domain

In the Healthcare domain ICT has 35 years of experience in linking systems under the header interoperability / Medical Data Exchange. The number of ICT engineers in this area has increased over the years, and the company combined their expertise in the Healthcare vertical. Their expertise goes way beyond technology nowadays, as it now also covers sector and broad and extensive domain know-how. Initially, ICT's operating domain was the hospitals/institutions in general. Nowadays ICT Healthcare focuses more specifically on medical data exchange within medical software development, and with a specialization in the 'niche' market of radiation therapy. Radiotherapy is a niche market with few active providers and a market in which customized solutions are virtually unheard of. ICT has made a strategic choice to focus its Medical Data Exchange-related efforts on the fields of radiation therapy and big data domains such as (digital) pathology. ICT has multiple customers in the radiation therapy domain varying from companies, institutions to standardization committees.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUOUNRSUABAAR
Date   Source Headline
9th May 20247:00 amRNSCancellation - Advanced Oncotherapy Plc
3rd May 20248:54 amRNSFurther update on financing discussions
2nd Apr 20243:50 pmRNSFurther update on financing discussions
29th Feb 20245:19 pmRNSFurther update on financing discussions
1st Feb 20247:00 amRNSFurther update on financing discussions
9th Jan 20249:00 amRNSUpdate on Financing Discussions
23rd Oct 20237:00 amRNSUpdate on Financing and Current Financial Position
17th Jul 20237:00 amRNSRecapitalisation and funding plan, update on FSP
30th Jun 20235:00 pmRNSTotal Voting Rights
30th Jun 20237:30 amRNSSuspension - Advanced Oncotherapy PLC
30th Jun 20237:15 amRNSUpdate on financing, suspension of trading on AIM
29th Jun 20231:35 pmRNSHolding(s) in Company
29th Jun 20239:59 amRNSForm 8.3 - Advanced Oncotherapy PLC
28th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy PLC
27th Jun 202310:29 amRNSForm 8.3 - Advanced Oncotherapy
27th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy
26th Jun 20234:26 pmRNSForm 8.3 - Advanced Oncotherapy
26th Jun 202310:57 amRNSPartial conversion of Convertible Notes
23rd Jun 202311:05 amRNSHolding(s) in Company
23rd Jun 20239:30 amRNSForm 8.3 - Advanced Oncotherapy PLC
20th Jun 20235:28 pmRNSHolding(s) in Company
19th Jun 20235:56 pmRNSPartial conversion of Convertible Notes
19th Jun 20231:48 pmRNSForm 8.3 - Advanced Oncotherapy PLC
16th Jun 20236:23 pmRNSIssue of warrants
13th Jun 202311:46 amRNSForm 8.3 - Advanced Oncotherapy PLC
31st May 20235:57 pmRNSUpdate on financing and convertible notes
30th May 202310:42 amRNSForm 8.3 - Advanced Oncotherapy Plc
24th May 20235:54 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
24th May 20235:29 pmRNSForm 8.3 - Advanced Oncotherapy - Cosylab d.d.
22nd May 20232:59 pmRNSForm 8.3 - Advanced Oncotherapy plc
19th May 202312:09 pmRNSForm 8.3 - Advanced Oncotherapy PLC
17th May 20232:58 pmRNSForm 8.3 - Advanced Oncotherapy plc
15th May 202311:36 amRNSUpdate on Convertible Note & Loan Extension
15th May 20239:19 amRNSForm 8.3 - Advanced Oncotherapy Plc
12th May 202312:53 pmRNSForm 8.3 - Advanced Oncotherapy - Minmetco Limited
11th May 20235:14 pmRNSForm 8.3 - Advanced Oncotherapy - eQ Blue Planet
11th May 202311:17 amRNSForm 8.3 - Advanced Oncotherapy - Atlantic Cedar
10th May 202311:34 amRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:40 pmRNSForm 8.3 - Advanced Oncotherapy - Baltisches Haus
9th May 20234:37 pmRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:36 pmRNSForm 8.3 - Advanced Oncotherapy plc
5th May 20238:56 amRNSFORM 8.3 - Advanced Oncotherapy
5th May 20237:00 amRNSAdditional funding from Secured Convertible Note
4th May 20235:01 pmRNSForm 8.3 - Advanced Oncotherapy Plc
4th May 20233:55 pmRNSChange of Registered Office
3rd May 20236:19 pmRNSRule 2.9 Announcement
3rd May 20234:28 pmRNSForm 8.3 - Advanced Oncotherapy PLC
2nd May 20236:19 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
18th Apr 20237:00 amRNSStrategic review and formal sale process
31st Mar 20236:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.